| Autor: |
Alfonso Cortés, Elena López-Miranda, Adela Fernández-Ortega, Vicente Carañana, Sonia Servitja, Ander Urruticoechea, Laura Lema-Roso, Antonia Márquez, Alexandros Lazaris, Daniel Alcalá-López, Leonardo Mina, Petra Gener, Jose Rodríguez-Morató, Gabriele Antonarelli, Antonio Llombart-Cussac, José Pérez-García, Javier Cortés |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Breast, Vol 78, Iss , Pp 103834- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1532-3080 |
| DOI: |
10.1016/j.breast.2024.103834 |
| Popis: |
Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without gBRCA1/2mut and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1. Results: Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8–88.2). Conclusions: The observed results could prompt further investigation. Trial: ClinicalTrials.gov identifier NCT03367689. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full Text from ScienceDirect